The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA after the ...

The recent success story of twice yearly shots of Lenacapavir preventing HIV in over 96 percent of at-risk people and the Gilead granting royalty-free voluntary licenses to six generic pharma globally ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

From an anal PrEP douche to the first women-controlled HIV prevention product, here's all the new HIV prevention products ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...